Job offersmore »
- CEO - Prague
- Plant Specialist - Melbourne, Australia
- General Manager European Region - Bologna, Italy
- Einkaufsverantwortlicher / Kundenbetreuer - Die Schweiz
- Continuous Improvement Specialist - Berkel en Rodenrijs, Nederland
- Innovation Leader - Johnston (Iowa), USA
- VP of Sales - Montreal, Canada
- IPM Consultant - Adelaide Plains, Australia
- National Nursery Manager - Australia
- Substrate Grower - Launceston CBD, Tasmania
Top 5 - yesterday
Top 5 - last week
Top 5 - last month
Exchange ratesmore »
US: Cannabis Science reports being on targetCannabis Science, a U.S. company specializing in the development of cannabinoid-based medicines, announces that the company has already achieved a good number of its goals for 2017. Cannabis Science is aggressively expanding its corporate footprint in legal states throughout the USA, to help self-medicating patients with multiple critical ailments.
One of CBIS' accomplishments in 2017 was the successful launch of the CBIS Native American Sovereign Education Initiative package. This has proven to be quite successful with the University opportunities, land preparation, economic stimulus, regulatory guidelines, local and international government relations, laboratories, cultivation procedures, and product manufacturing utilizing cannabis and/or industrial hemp. The company is very pleased with the industrial hemp planting currently in progress and very excited to report specific progress moving forward. The company is expanding its land deals across the country and is moving the grow pods to key locations for special cloning and research projects.
"I am particularly excited about the Cannabis Science Consortium. This consortium, led by CBIS, will include collaborations with research and patient-care institutions in the U.S. and worldwide. Our Consortium provides CBIS with a global platform to develop cannabinoid-based medicines and to undertake clinical trials for several medicines that have the potential to help so many people. By partnering with leading individuals and institutions, we hope to increase the cannabinoid-based medicines in our development pipeline, and shorten the release time. CBIS, Inc. is working in three major areas: more efficient and effective delivery of cannabinoids to the sites of disease; understanding how to create the right mixtures of cannabinoids; and defining the diseases that may benefit from cannabinoid therapeutics. In these endeavors we are informed by the 2016 National Academies of Sciences, Engineering, and Medicine Report on 'The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research'," stated Cannabis Science Inc., Dr. Allen Herman, Chief Medical Officer (CMO).
CBIS has released several new products for self-medicating patient testing and observational studies, including the CBIS Metered Dose Inhaler (MDI) to target Chronic Obstructive Pulmonary Disease (COPD) and Asthma; the CBIS Transdermal Patch to target chronic pain; and the CBIS Suppository to target severe pain and other symptoms associated with cancers, anxiety, and insomnia. In addition to these and other CBIS products, the company continues to invest significantly in the research, development, and clinical trials for new cannabinoid formulations and innovative delivery systems for numerous critical indications.
Another accomplishment of note is CBIS' registration with the U.S. federal government to receive contracts and grants. CBIS completed its registration in the System for Award Management (SAM), and applied for and received a Commercial and Government Entity (CAGE) Code from the Defense Logistics Agency. By successfully completing this process, CBIS has access to a market of over $192 billion in contracts and over $450 billion in grants annually.
For more information:
19800 MacArthur Blvd.
Irvine, CA 92612
Tel: +1 (888) 263-0832
Fax: +1 (888) 554-2137
Publication date: 7/6/2017
Other news in this sector: